Consequently, PROX1 and MTA1 are regarded as useful biomarkers for the diagnosis, prognosis, and treatment of malignancies in humans; nevertheless, additional research is required to thoroughly evaluate their function in cancer therapy and their potential clinical application. The gene discussed is MTA1; the disease is cancer.